Sarkar Jit, Nargis Titli, Tantia Om, Ghosh Sujoy, Chakrabarti Partha
Division of Cell Biology and Physiology, Indian Institute of Chemical Biology (CSIR), Kolkata, India.
Academy of Scientific and Innovative Research, Ghaziabad, India.
Front Endocrinol (Lausanne). 2019 Jul 25;10:505. doi: 10.3389/fendo.2019.00505. eCollection 2019.
Increase in circulating dipeptidyl peptidase-4 (DPP4) activity and levels has been reported to associate both with hyperglycemia and obesity. Here we aim to decipher the role of enhanced plasma DPP4 activity in obese type 2 diabetes (T2DM) patients. Plasma DPP4 levels and activity were measured in obese and non-obese newly diagnosed T2DM patients ( = 123). Visceral and subcutaneous adipose tissue DPP4 expression and activity were determined in 43 obese subjects (T2DM = 21 and non-T2DM = 22). 20 subjects undergoing Mini-Gastric Bypass (MGB) surgery were followed up over 4-6 weeks for plasma DPP4. Plasma DPP4 levels and activity both were increased in T2DM patients compared to control group. However, DPP4 levels and not DPP4 activity were increased in obese T2DM patients compared to non-obese T2DM (62.49 ± 26.27 μg/ml vs. 48.4 ± 30.98 μg/ml, respectively, = 0.028). DPP4 activity in visceral adipose tissue (VAT) from obese T2DM and obese non-T2DM groups were similar (5.05 ± 3.96 nmol/min/ml vs. 5.83 ± 4.13 nmol/min/ml respectively, = 0.548) in spite of having increased DPP4 expression in the obese T2DM group. Moreover, in obese patients, plasma DPP4 levels and activity did not show any significant change after weight reduction and glycemic control following MGB surgery. Enhanced plasma DPP4 activity in T2DM occurs independently of obesity. Thus, adipose derived DPP4 may not be playing any significant role in glycemic deregulation in obese T2DM patients.
据报道，循环二肽基肽酶4（DPP4）活性和水平的升高与高血糖和肥胖均有关联。在此，我们旨在阐明血浆DPP4活性增强在肥胖2型糖尿病（T2DM）患者中的作用。对肥胖和非肥胖新诊断的T2DM患者（n = 123）测定血浆DPP4水平和活性。在43名肥胖受试者（T2DM = 21名，非T2DM = 22名）中测定内脏和皮下脂肪组织DPP4的表达和活性。对20名接受迷你胃旁路术（MGB）的受试者随访4 - 6周，检测其血浆DPP4。与对照组相比，T2DM患者的血浆DPP4水平和活性均升高。然而，与非肥胖T2DM患者相比，肥胖T2DM患者的DPP4水平升高，而DPP4活性未升高（分别为62.49±26.27μg/ml和48.4±30.98μg/ml，P = 0.028）。尽管肥胖T2DM组的DPP4表达增加，但肥胖T2DM组和肥胖非T2DM组内脏脂肪组织（VAT）中的DPP4活性相似（分别为5.05±3.96 nmol/min/ml和5.83±4.13 nmol/min/ml，P = 0.548）。此外，在肥胖患者中，MGB手术后体重减轻和血糖控制后，血浆DPP4水平和活性未显示任何显著变化。T2DM患者血浆DPP4活性增强独立于肥胖发生。因此，脂肪源性DPP4可能在肥胖T2DM患者的血糖失调中未发挥任何重要作用。
